Sodium
Active ingredient
Sold as Bridged Phenyl Combination… · GAVISCON ORIGINAL ANISEED… · MAGNESIUM TRISILICATE…
- Drug class
- -
- Availability
- Prescription and OTC
- Routes
- Intravenous, Oral, Topical
- Markets covered
- 3
- Products on record
- 55
- FDA reports (12 mo)
- 92,881
Overview
Sodium is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 44 | May 29, 2026 |
| CA Canada | Health Canada | 6 | July 24, 2025 |
| US United States | FDA | 5 | January 28, 2026 |
GBUnited Kingdom· MHRA
44 products
Uses
g. nutrition poor in fibres, lack of physical activity, as well as diseases requiring easy defaecation). Emptying the colon before diagnostic or therapeutic procedures in the rectum.
How to take
CACanada· Health Canada
6 products
Uses
20 Product Monograph: Sodium Nitroprusside for Injection Page 3 of 22 PrSodium Nitroprusside for Injection 25 mg/mL PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Dosage Form / Strength Nonmedicinal Ingredients Intravenous Solution for injection; 25 mg/mL Water for Injection INDICATIONS AND CLINICAL USE Sodium Nitroprusside for Injection is indicated for the treatment of acute hypertension, refractory to standard therapeutic measures.
Sodium Nitroprusside for Injection is also indicated for producing controlled hypotension during anesthesia in order to reduce bleeding in surgical procedures, where surgeon and anesthesiologist deem it appropriate. In each case, the benefit-risk ratio should be carefully considered on an individual basis.
CONTRAINDICATIONS Patients who are hypersensitive to sodium nitroprusside or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING. , arteriovenous shunt or coarctation of the aorta).
USUnited States· FDA
5 products
Uses
INDICATIONS & USAGE
Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized.
Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside is also indicated for the treatment of acute congestive heart failure.
How to take
Sources & citations
- [1]MHRA (UK) · PL284180002 · revised December 27, 2024
- [2]Health Canada (DPD) · 02450089 · revised March 22, 2025
- [3]FDA DailyMed · 01841345-bed3-45… · revised July 22, 2021 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.